{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033494","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.508034+00:00","generated_at":"2026-06-04T23:11:06.835865+00:00","sec_items":["1.01","1.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea raises up to $34M in private placement; FDA clears IND for APR-1051","bullets":["$16M upfront gross proceeds from private placement; up to $18M additional from warrant exercise.","Financing led by Sphera Healthcare with Nantahala, DAFNA, Exome, Stonepine, and insiders.","Shares at $7.29; Tranche A warrants at $7.29 and Tranche B at $9.1125, tied to RP2D milestones.","FDA cleared IND for APR-1051, a next-gen WEE1 inhibitor for Cyclin E overexpressing cancers.","Phase 1 ACESOT-1051 trial to start H1 2024; update expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033494","json":"https://secwatch.observer/filing/0001104659-24-033494.json","markdown":"https://secwatch.observer/filing/0001104659-24-033494.md","text":"https://secwatch.observer/filing/0001104659-24-033494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/0001104659-24-033494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/tm248508d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:11:06.835865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bb9412f46ff44bdaeb0721aca1bab2e110e4c6f","claim":"Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of approximately $16.0 million (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Aprea Therapeutics, Inc. (the \"Company\") entered into a securities purchase agreement (the \"Securities Purchase Agreement\") with certain investors (the \"Purchasers\"), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares (the \"Private Placement Shares\") of the Company’s Common Stock, par value $0.001 per share (\"Common Stock\") at a purchase price of $7.29 per share, (ii) pre-funded Common Stock purchase warrants (the \"Pre-Funded Warrants\") to purchase an aggregate of up to 507,076 shares of Common Stock at an exercise price of $0.001 per share, (iii) Tranche A Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $7.29 per share (the \"Tranche A Warrants\"), and (iv) Tranche B Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $9.1125 per share (the \"Tranche B Warrants\"","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/0001104659-24-033494-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"aggregate gross proceeds of approximately $16.0 million"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}